Showing results (1711-1720 of 1,743) with videos related to
Sort By:
Pageof 175
International Journal of Chronic Obstructive Pulmonary Disease|June 11, 2021
Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled TrialsMalcolm Begg, J Nicole Hamblin, Emily Jarvis, et al.Cold Spring Harbor Molecular Case Studies|April 4, 2018
Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencingAnna Schuh, Helene Dreau, Samantha J L Knight, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.Ebiomedicine|October 1, 2022
Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infectionGabriella Captur, James C Moon, Constantin-Cristian Topriceanu, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 18, 2016
Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocolsJudith A E M Zecha, Judith E Raber-Durlacher, Raj G Nair, et al.Journal of Medicinal Chemistry|December 20, 2019
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity TargetZoë A Henley, Augustin Amour, Nick Barton, et al.Journal of Medicinal Chemistry|August 14, 2020
Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine GliomaDavid Smil, Jong Fu Wong, Eleanor P Williams, et al.Blood|August 29, 2015
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLLRomain Guièze, Pauline Robbe, Ruth Clifford, et al.Journal of Medicinal Chemistry|August 25, 2015
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory DiseaseKenneth Down, Augustin Amour, Ian R Baldwin, et al.Antimicrobial Agents and Chemotherapy|November 25, 2004
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimenSimon J F Macdonald, Keith G Watson, Rachel Cameron, et al.Pageof 175